Adverse Events Following Oxford-Astrazeneca's COVID-19 Vaccine among Health Care Workers in a Tertiary Care Teaching Hospital: A Prospective Observational Study
VirusDisease
; 34(1):103, 2023.
Article
in English
| EMBASE | ID: covidwho-2320030
ABSTRACT
Background:
The ubiquitous elixir for mortality and morbidity inflicted by severe acute respiratory syndrome virus (SARS-CoV-2) has been a vaccine. These vaccines were approved for emergency use authorization by health authorities based on limited data from clinical trials. Hence, there was a need for active surveillance of vaccinees to monitor for safety. Objective(s) This study reports adverse events following immunization with Oxford-AstraZeneca's COVID-19 vaccine (COVISHIELD). Material(s) and Method(s) The present study is an observational follow- up study to assess any adverse event occurrence following immunization (AEFI) within 7 days of vaccination among all eligible participants who were vaccinated. A structured safety surveillance questionnaire was administered consecutively to 714 participants. Vaccinees were observed for thirty minutes and followed telephonically for adverse events. Result(s) The overall incidence of any AEFI within 7 days was found to be 136/1000 vaccinations for the first dose. Out of total, 97 recipients reported with adverse events, 76.3% had AEFI within 24 h with fever as the most common symptom reported. The incidence of AEFI's was found to be associated with gender (P<0.02), age group (P<0.05) and occupation (P<0.05). No cases of hospitalization, disability or death were reported. Conclusion(s) Most of the adverse events were short-lived and observed in the first 24 h of vaccination. Incidence decreased in subsequent days and as no significant life-threatening adverse event was observed, this study might help reduce hesitancy for vaccination among the population and thus help reduce transmission of this highly contagious disease.
Adverse events following immunization; covid-19; covishield vaccine; healthcare workers; adult; adverse drug reaction; clinical trial; communicable disease; conference abstract; controlled study; coronavirus disease 2019; disability; drug safety; female; fever; follow up; gender; groups by age; health care personnel; hospitalization; human; immunization; incidence; major clinical study; male; observational study; occupation; prospective study; questionnaire; side effect; teaching hospital; tertiary health care; vaccination; vaccinee; vaxzevria
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Language:
English
Journal:
VirusDisease
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS